Angela Cacace

Arvinas (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

27h-index3.1kcitations63works20.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genetics and Neurodevelopmental Disorders(11), Alzheimer's disease research and treatments(9), Autism Spectrum Disorder Research(6), Protein Kinase Regulation and GTPase Signaling(6), Muscle Physiology and Disorders(6)

Publications63 total

1158 Preclinical antitumor activity of potent and orally bioavailable PROTAC hematopoietic progenitor kinase 1 (HPK1) degraders as monotherapy or combined with an anti-programmed death-1 (PD-1) antibody
Regular and Young Investigator Award Abstracts·2025Open Access
First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of ARV-102, a PROTAC LRRK2 degrader, in healthy volunteers
Parkinsonism & Related Disorders·2025· 3 cited
New therapies on the horizon: Targeted protein degradation in neuroscience
Cell chemical biology·2024· 25 citedOpen Access
Anti-acetylated-tau immunotherapy is neuroprotective in tauopathy and brain injury
Molecular Neurodegeneration·2024· 18 citedOpen Access
Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules
Nature Structural & Molecular Biology·2024· 55 cited
Fragile X Syndrome Patient–Derived Neurons Developing in the Mouse Brain Show FMR1-Dependent Phenotypes
Biological Psychiatry·2022· 2 cited
Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies
Molecular Therapy — Nucleic Acids·2022· 23 citedOpen Access
Acute Neurotoxicity of Antisense Oligonucleotides After Intracerebroventricular Injection Into Mouse Brain Can Be Predicted from Sequence Features
Nucleic Acid Therapeutics·2022· 54 citedOpen Access
Fragile X syndrome patient-derived neurons developing in the mouse brain show <i>FMR1</i> -dependent phenotypes
2021Open Access
Current directions in tau research: Highlights from Tau 2020
Alzheimer s & Dementia·2021· 72 citedOpen Access
Targeted Protein Degradation
Methods in molecular biology·2021· 3 cited
Human-mouse chimeric Fragile X syndrome model reveals FMR1-dependent neuronal phenotypes
Research Square (Research Square)·2020Open Access
p38α Regulates Expression of DUX4 in a Model of Facioscapulohumeral Muscular Dystrophy
Journal of Pharmacology and Experimental Therapeutics·2020· 42 citedOpen Access
Allele-Selective Knockdown of MYH7 Using Antisense Oligonucleotides
Molecular Therapy — Nucleic Acids·2020· 23 citedOpen Access
Partial FMRP expression is sufficient to normalize neuronal hyperactivity in Fragile X neurons
European Journal of Neuroscience·2019· 42 citedOpen Access
Author response for "Partial FMRP expression is sufficient to normalize neuronal hyperactivity in Fragile X neurons"
2019
Author response for "Partial FMRP expression is sufficient to normalize neuronal hyperactivity in Fragile X neurons"
2019
P.43Targeting DUX4 expression, the root cause of FSHD: identification of a drug target and development candidate
Neuromuscular Disorders·2019
P38α Regulates Expression of DUX4 in Facioscapulohumeral Muscular Dystrophy
2019· 3 citedOpen Access
O5‐04‐05: A NEW THERAPEUTIC STRATEGY FOR TAUOPATHIES: DISCOVERY OF HIGHLY POTENT BRAIN PENETRANT PROTAC<sup>TM</sup> DEGRADER MOLECULES THAT TARGET PATHOLOGIC TAU PROTEIN SPECIES
Alzheimer s & Dementia·2019· 2 cited
page 1 of 4Next →

Frequent Co-authors

Owen B. Wallace(6), Hao Wu(5), I. Bernard Weinstein(5), John Corradi(5), Rudolf Jaenisch(4), Edward K. Han(4), Jeffrey M. Brown(4), John E. Macor(4), Martyn Banks(4), John D. Graef(3), Deborah K. Morrison(3), Charles F. Albright(3), Jere E. Meredith(3), Amy Easton(3), Peter Hagedorn(3), Richard E. Olson(3), Stephen E. Mercer(3), Marianne L. Jensen(3), Lorin A. Thompson(3), Aaron N. Chang(3)